Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Omeprazole in Pancreatic Cancer
NCT04930991Phase 1Terminated
- Sponsor
- University of Oklahoma
- Start
- Sep 2021
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of omeprazole in exocrine pancreatic cancer (2 arms), sponsored by University of Oklahoma. Primary endpoints: Proportion at 2 years and Safety and Tolerability at 2 years. Started Sep 2021; status: terminated.
02
Drugs
omeprazole
03
Conditions
exocrine pancreatic cancer
Beyond the preview
Go deeper on NCT04930991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04930991.